Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

about

Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.

P2860

Q55285563-F570DEF6-C84C-4700-B342-57BA547E4509

P2860

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Item

http://www.wikidata.org/entity/Q36256870

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@ast

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@en

type

Item

label

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@ast

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@en

prefLabel

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@ast

Rapidly fatal advanced EGFR-mu ...... notyping in clinical practice.

@en

P1476

Rapidly fatal advanced EGFR-mu ...... enotyping in clinical practice

@en

P2093

Daniel B Costa

http://www.w3.org/2001/XMLSchema#string

Danielle C McDonald

http://www.w3.org/2001/XMLSchema#string

Deepa Rangachari

http://www.w3.org/2001/XMLSchema#string

Erik Folch

http://www.w3.org/2001/XMLSchema#string

Lauren Drake

http://www.w3.org/2001/XMLSchema#string

Mark S Huberman

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

P304

41-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CTARC.2016.07.001

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul A VanderLaan

P577

2016-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28111612

http://www.w3.org/2001/XMLSchema#string

P932

5241076

http://www.w3.org/2001/XMLSchema#string

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

about

P2860

P2860

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932